Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe

Read the original here:
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI

Link:
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET

Continue reading here:
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge® (omidubicel-onlv)

Go here to read the rest:
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.

More here:
Ocuphire Pharma to Present in the BIO CEO & Investor Conference

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations.

Read more from the original source:
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual...

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)

Visit link:
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.

Follow this link:
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

The rest is here:
Curia Appoints Steve Lavezoli as Vice President, Biologics

New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG

See original here:
Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany

Originally posted here:
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

PARAMUS, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today announced that Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics, will present and host one-on-one meetings at the BIO CEO & Investor Conference being held in New York City, February 26-27, 2024. Details for the event are as follows:

See the original post:
Starton Therapeutics to Present at BIO CEO & Investor Conference 2024

FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, to be effective at 5:00 p.m. Eastern Standard Time, Wednesday, February 28, 2024. Celularity’s Class A common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Thursday, February 29, 2024, under the current trading symbol, “CELU.” The reverse stock split was approved by Celularity’s stockholders on February 22, 2024, and is intended to increase the per share trading price of its Class A common stock to enable Celularity to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Visit link:
Celularity Announces 1-for-10 Reverse Stock Split

Company Announcement

Follow this link:
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest-grossing pharmaceutical products in the world, with sales in the U.S. of nearly $12.2 billion[1]. Teva is Alvotech’s strategic partner for the exclusive commercialization of SIMLANDI in the United States.

See the original post:
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free...

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece:

Go here to see the original:
Statement of Renovaro Inc

Company Announcement

View original post here:
Genmab Publishes 2023 Annual Report

Liège, Belgium – February, 14 2024 – 6PM CET – Non-regulated information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a pivotal Phase 3 clinical trial for Tranexamic Acid Oral Rinse.

See more here:
Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024

Read the rest here:
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.

See more here:
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference